Hepatogenous diabetes: Is it a neglected condition in chronic liver disease? by García Compeán, Diego et al.
Hepatogenous diabetes: Is it a neglected condition in 
chronic liver disease?
Diego García-Compeán, José Alberto González-González, Fernando Javier Lavalle-González, 
Emmanuel Irineo González-Moreno, Jesús Zacarías Villarreal-Pérez, Héctor Jesús Maldonado-Garza
Diego García-Compeán, José Alberto González-González, 
Emmanuel Irineo González-Moreno, Héctor Jesús Maldonado-
Garza, Gastroenterology Service and Department of Internal 
Medicine, University Hospital “Dr. José E. González” and Medical 
School, Universidad Autónoma de Nuevo León, Monterrey 64320, 
México
Fernando Javier Lavalle-González, Jesús Zacarías Villarreal-
Pérez, Endocrinology Service and Department of Internal 
Medicine, University Hospital “Dr. José E. González” and 
Medical School, Universidad Autónoma de Nuevo León, 
Monterrey 64320, México
Author contributions: All the authors contributed equally to the 
revision of the content of this manuscript; and García-Compeán 
D conceived and wrote the editorial.
Supported by the Department of Endocrinology and Service 
of Gastroenterology of the Faculty of Medicine, Autonomous 
University of Nuevo Leon.
Conflict-of-interest statement: All authors declare no conflict 
of interest.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Diego García-Compeán, MD, MMSc, 
Gastroenterology Service and Department of Internal Medicine, 
University Hospital “Dr. José E. González” and Medical School, 
Universidad Autónoma de Nuevo León, Madero y Gonzalitos S/
N, Monterrey 64320, México. digarciacompean@prodigy.net.mx
Telephone: +52-81-83487315 
Fax: +52-81-89891381
Received: December 23, 2015  
Peer-review started: December 24, 2015
First decision: January 13, 2016
Revised: January 20, 2016
Accepted: February 20, 2016  
Article in press: February 22, 2016
Published online: March 14, 2016
Abstract
Diabetes mellitus (DM) that occurs because of chronic 
liver disease (CLD) is known as hepatogenous diabetes 
(HD). Although the association of diabetes and liver 
cirrhosis was described forty years ago, it was scarcely 
studied for long time. Patients suffering from this 
condition have low frequency of risk factors of type 
2 DM. Its incidence is higher in CLD of viral, alcoholic 
and cryptogenic etiology. Its pathophysiology relates 
to liver damage, pancreatic dysfunction, interactions 
between hepatitis C virus (HCV) and glucose meta-
bolism mechanisms and genetic susceptibility. It 
associates with increased rate of liver complications 
and hepatocellular carcinoma, and decreased 5-year 
survival rate. It reduces sustained virological response 
in HCV infected patients. In spite of these evidences, 
the American Diabetes Association does not recognize 
HD. In addition, the impact of glucose control on 
clinical outcomes of patients has not been evaluated. 
Treatment of diabetes may be difficult due to liver 
insufficiency and hepatotoxicity of antidiabetic drugs. 
Notwithstanding, no therapeutic guidelines have been 
implemented up to date. In this editorial, authors 
discuss the reasons why they think that HD may be a 
neglected pathological condition and call attention to 
the necessity for more clinical research on different 
fields of this disease.
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fat) and pancreatic β cell dysfunction, with the former 
accounting for transition from impaired glucose 
tolerance to DM and worsening in parallel with 
the severity of liver disease[2,8,9]. Liver dysfunction 
exerts a ‘‘toxic” effect on pancreatic islets, playing a 
major pathophysiological role in the development of 
diabetes[2]. In fact, HD usually reverses or ameliorates 
after successful liver transplant, thus suggesting that it 
directly relates to loss of liver function[10,11]. 
In addition, recently described evidences of 
direct interactions of HCV with glucose metabolism 
mechanisms in non-cirrhotic patients, have placed the 
HCV also as a diabetogenic agent[12,13]. Autoimmune 
phenomena, direct cytotoxic effects on pancreatic 
β cells and a blockage of insulin receptors at the 
cellular level induced by HCV proteins have been 
demonstrated[14-16]. HCV core up regulates suppressor 
of cytokine signaling 3 expression that induces 
proteosomal degradation of insulin receptor substrates 
1 and 2 (which are central molecules of the insulin-
signaling cascade)[17] and increases gluconeogenesis[18]. 
In one study, the clearance of HCV with antiviral 
therapy in patients with chronic hepatitis C, significantly 
reduced insulin resistance, improved pancreatic β cell 
function and increased hepatic expression of insulin 
receptor substrate 1 and 2[19]. Notwithstanding, these 
relevant findings need to be reproduced in prospective 
studies with large number of patients.
Furthermore, in alcoholic CLD, pancreatic damage 
may be involved in the genesis of diabetes[10,20]. Finally, 
genetic factors rather than only liver or pancreatic 
damage may also be involved in the susceptibility to 
develop HD as it was shown in a recent study with 
367 patients with liver cirrhosis of diverse etiology. 
Polymorphisms of the transcription factor 7-like 2 
gene, (a gene that has been associated with DM and 
cancer risk) were significantly associated with HD[21].
In the other side, diagnosis of HD may be difficult 
since clinical manifestations of HD in the early stages 
of liver disease are virtually absent. Fasting plasma 
glucose may be normal. Only insulin resistance 
(measured by HOMA-IR Index) and glucose intolerance 
detected by OGTT may be observed. As liver disease 
progresses, diabetes becomes clinically manifested, 
therefore overt HD may be considered as a marker 
of liver function deterioration[22]. When diabetes is 
overt, discrimination between HD and type 2 DM may 
be difficult. HD should be suspected in lean patients 
without family history of diabetes, hyperlipidemia or 
arterial hypertension. In a recent study comparing 
patients with HD vs patients with type 2 DM, the ratios 
of postprandial plasma glucose to fasting plasma 
glucose, fasting insulin and HOMA-Insulin Resistance 
index were significantly higher in patients with HD[23].
What is the importance of diagnosing HD? For 
answering this question, it is mandatory to be aware 
of the impact of this entity on the clinical outcomes 
of patients with CLD. Though some reports described 
the diabetogenic nature of liver cirrhosis four decades 
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Core tip: The authors expose arguments, which indicate 
that hepatogenous diabetes has not received enough 
attention for many years. They provide published 
evidences that make them to propose that this entity 
should be considered as a complication of chronic 
liver disease, and that an oral glucose tolerance test 
must be done to patients without previous diabetes 
mellitus showing normal fasting plasma glucose 
levels. They also propose that an adequate treatment 
of hyperglycemia with liver friendly-drugs must be 
undertaken for reducing complications and mortality. 
They also highlight the lack of research on long-
term treatment of diabetes and the lack of treatment 
recommendations for these vulnerable patients.
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One of the most important questions regarding 
chronic liver disease (CLD) and diabetes mellitus 
(DM) association relates to the clinical implication of 
this relationship. Currently, it is known that patients 
with CLD may have two types of DM: hereditary Type 
2 DM and hepatogenous diabetes (HD). The former 
one is frequently associated to metabolic syndrome 
that gives rise to non-alcoholic fatty liver disease, 
liver cirrhosis and hepatocellular carcinoma (HCC). 
The latter one appears after onset of liver disease. 
HD can be identified in CLD patients without previous 
history of DM in the absence of standard risk factors 
of type 2 DM such as high body mass index, family 
history of diabetes and hyperlipidemia[1]. It has been 
reported that around 80% to 85% of these patients - 
even those with normal fasting glucose levels - may 
have glucose intolerance or DM[2,3]. This abnormality is 
higher in patients with liver disease due to hepatitis C 
virus (HCV), alcoholic and cryptogenic etiology. Despite 
these evidences, the American Diabetes Association[4] 
does not recognize HD.
Although the diabetogenic potential of liver 
cirrhosis was initially described in the 60’s[5], Petrides 
et al[6] first used the term HD in the 90’s. Its use did 
not extend, probably because the concept was then 
misunderstood.
HD may result from decreased extraction of 
insulin by the damaged liver and the presence of 
portosystemic shunts that lead to hyperinsulinemia, 
which is potentiated by increases in glucagon, growth 
hormone, insulin-like growth factor, free fatty acids 
and cytokines[7]. These abnormalities induce insulin 
resistance of peripheral tissues (muscles, liver and 
ago, only three prospectively conducted studies 
have assessed its impact on survival up to date[24-26]. 
All of them demonstrated that HD was significantly 
associated with lower 5-year cumulated survival. The 
majority of deceased patients died of liver-related 
causes. They also found that besides HD, liver failure 
and old age were independent predictors of death, 
which suggest that these conditions may combine 
synergistically[24-26]. 
HD is also associated with increased rate of 
liver complications such as hepatic encephalopathy, 
esophageal variceal hemorrhage, spontaneous primary 
peritonitis and renal impairment[27-30]. In HCV infected 
patients, HD and insulin resistance are significantly 
associated with liver fibrosis, increased complications 
and mortality rates[31,32]. HD also associates with 
decreased sustained virological response rates to inter-
feron-based treatments[16,33]. Unexpectedly, reported 
cardiovascular complications are low compared to 
liver-related ones[24-26]. This may be explained because 
of presumptive acceleration of liver failure induced 
by HD probably shortens the time in which diabetic 
cardiovascular complications can take place. In addition, 
coagulation impairment induced by liver failure, which 
would act as protective factor, has been evoked.
In the other side, pre-transplant DM is a risk factor 
for the development of diabetes after transplant[34]. 
This post-transplant diabetes associates with increased 
mortality, infections and acute graft rejection[35,36]. 
Therefore, identification of HD before transplant is of 
primary importance in order to improve post-transplant 
outcomes. 
Finally, DM and glucose intolerance were found to 
be associated with the development of HCC and biliary 
tract cancer in a study with infected HCV patients and 
in a large European cohort of individuals with self-
reported diabetes data[37,38]. In addition, diabetes was 
associated with significant lower cumulative survival 
rate in male patients with HCC and HCV[37]. It is 
unclear how diabetes influences hepatocarcinogenesis. 
Oxidative stress may be an important factor, also 
hyperinsulinemia, which acts as growth factor through 
activation of 5’ adenosine monophosphate-activated 
protein kinase, may be involved[39]. Recent studies 
suggested that liver inflammation, induced by diabetes, 
might lead to exposure of hepatocytes to increased 
activation of signaling pathways, followed by lack of 
apoptosis and uncontrolled hepatocyte proliferation[40]. 
The mechanism by which HD may deteriorate 
liver function giving rise to adverse outcomes is 
not precisely known. It may increase fibrosis and 
inflammation through the activity of pro-inflammatory 
and fibrogenic adipokynes such as: tumor necrosis 
factor alpha, tumor growth factor beta-1, resistin, 
leptin, hepatic growth factor and adiponectine[41-43]. 
In addition, immunosuppression induced by HD, may 
also be involved in mortality by increasing incidence 
of infections[27]. More studies are necessary in order to 
clear these issues.
Based on the above-discussed evidences, HD 
should be considered as a complication of CLD in the 
same way as hepatic encephalopathy, ascites, portal 
hypertension or hepatorenal syndrome. In addition, 
the described differences between hereditary type 2 
DM and HD regarding pathophysiology, risk factors, 
clinical features, effects on outcome and therapeutic 
results are strong reasons for diagnosing them as 
separated entities.
Whether or not, therapeutic control of hyperglycemia 
reduces complications and mortality rates of patients 
with HD is unknown[3]. Pharmacological treatment of 
diabetes is challenging and may be potentially harmful, 
particularly in those from Child-Pugh C group, due to 
altered drug metabolism and increased susceptibility of 
hypoglycemia and lactic acidosis[44,45]. Probably due to 
this reason, adequate control of hyperglycaemia can be 
achieved in only one third of patients, as was recently 
reported[46,47]. In addition, therapeutic guidelines or 
recommendations have not been established for these 
patients, and only few studies have assessed the long-
term safety of antidiabetic drugs in CLD patients, 
particularly in those with severe liver failure[44]. In spite 
of this lack of information, it is highly recommended 
to undertake an adequate control of plasma glucose 
levels through diet and lifestyle changes as soon as 
HD can be detected. For pharmacological treatment, 
sulphonylureas should be avoided in case of hepatic 
impairment[48]. Pioglitazone, metformin and acarbose 
have been proved safe and efficacious therapeutic 
agents[45]. Metformin has been administered during a 
mean period of 8 years with low frequency of noxious 
side effects, even in patients with moderate and 
advanced liver insufficiency. This medication reduced 
mortality and hepatocellular cancer in diabetic patients 
with liver cirrhosis[49,50]. It was suggested that there is 
an independent association of the use of exogenous 
insulin and sulphonylureas with the development of 
HCC and extrahepatic cancer. A recently published 
metanalysis, that evaluated whether the use of 
antidiabetic medications has any influence on the 
risk of HCC, showed metformin as protective agent 
and sulphonylureas and insulin as negative factors. 
Nevertheless, there was a high heterogeneity among 
studies included in the analysis and post-hoc analysis 
of randomized controlled trial did not reveal significant 
association between antidiabetic medications use 
and the risk of HCC[51]. More prospective studies are 
required for clearing if insulin therapy or sulphonylureas 
use increase the risk of HCC in CLD patients. 
Currently, incretin-based therapies, composed 
by drugs that target the incretin system and are 
not metabolized by the liver (such as injectable 
glucagon-like peptide-1 receptor agonists and oral 
inhibitors of dipeptidylpeptidase-4), are being assayed 
in cirrhotic patients and seem to be promising. In 
contrast to old glucose-lowering agents, these new 
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drugs were evaluated in specifically designed acute 
pharmacokinetic studies in patients with various 
degrees of hepatic impairment, and their safety was 
carefully analyzed in large clinical trials[52]. In patients 
from Child-Pugh C group and decompensated liver 
disease, insulin administration should be started only 
in in-hospital patients[53,54].
Finally, pending further research on these issues 
and based on the evidences currently available, we 
propose to undertake the following recommendations 
for CLD patients care: (1) Search DM in all patients. An 
OGTT must be done to patients without previous DM 
showing normal fasting plasma glucose levels[2,24-26]; 
(2) Classify DM as HD or T2 DM based on clinical 
and biochemical features previously described[1]; 
(3) Monitor liver and cardiovascular complications in 
patients with HD; (4) Begin a timely treatment of HD. 
For pharmacological therapy, liver function must be 
taken into account. Use only liver-friendly drugs[44,45]; 
(5) In HCV infected patients, administer preferably 
insulin sensitizers in order to increase sustained 
virological response to antiviral therapy; (6) Search DM 
before transplant in order to administer a treatment 
for improving post-transplant outcomes[34-36]; and (7) 
In Child-Pugh C patients with decompensated liver 
function start therapy with hypoglycemic drugs or 
insulin preferably in in-hospital patients.
Certainly, the precise value of some of the above-
proposed recommendations on the clinical outcomes 
of patients with CLD has not rigorously been assessed 
in well-conducted and high-quality clinical studies. 
Such studies will be welcomed since their information 
will allow the improvement of therapeutic results and 
clinical outcomes of these vulnerable patients. In 
addition, therapeutic guidelines diligently elaborated 
and supervised by endocrinologists and hepatologists 
together are extremely necessary.
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